deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE’s DNA-based prostate cancer risk assessment test to its clients nationwide.
Read More
The 2,400-patient study evaluates the Percepta Nasal Swab test’s ability to guide management decisions for patients with lung nodules.
Read More
The funding will support commercialization of the company’s extracellular vesicle-based liquid biopsy tests, starting with ovarian cancer screening.
Read More
A new survey reveals declining cancer screening rates among U.S. adults, but shows strong interest in innovative screening methods.
Read More
A nanoneedle patch offers a painless, non-invasive alternative to biopsies by collecting molecular information without removing tissue.
Read More